PEStore

Buyout PE

Kleoss Capital

Kleoss Capital acquires controlling stakes in established, profitable businesses, from Sandton, South Africa. It states a focus on healthcare & life sciences, financial services, industrials & manufacturing and transportation & logistics.

Disclosed holdings9
Earliest stated investment
HeadquartersSandton, South Africa
Largest single fundNot stated

Stated investment criteria

What Kleoss Capital says it buys

Read from Kleoss Capital’s own website in August 2026. This is what the firm says it buys, not what anyone has recorded it buying, and figures are shown in the currency the firm itself used - nothing here is converted. Every line links to the page it was read from.

Transaction typesManagement buyout1
People listed on its team page32

A stated mandate is a firm’s description of itself and was true of the page on the day it was read; firms widen and narrow what they will look at without updating the site. Kleoss Capital states that it will take either a controlling or a minority stake. The team figure counts the people the firm shows on one team page, so it is a floor rather than a headcount: firms that split their team across tabs or load it in pages will read low. Nothing here is a commitment by Kleoss Capital to consider any particular business, and nothing on this page is represented as being for sale.

Portfolio

Disclosed holdings

Companies Kleoss Capital lists on its own website. No investment years are published.

CompanyInvestedYears heldRecorded transaction
Bandag
Cdediabetes
Centre for Diabetes and Endocrinology
Dartcom
Debt Rescue
Kleosscapital
Real Foods
Realfoodsgroup
Trenstar

Compiled from Kleoss Capital’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.

Valuation context

Transaction values in Healthcare & Life Sciences

What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.

Median consideration$110m
Middle 50%$30m-$318m
Revenue multiple2.8×
EBITDA multiple12.5×

The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.

For owners

Own a healthcare & life sciences business?

The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.

Request a confidential valuation

For investors

Is this Kleoss Capital?

Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.

Claim or correct this profile

Targeted buyer search

Which hundred of these would actually buy your business?

A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.

See how it works

Comparable investors

Similar mandates

Other buyout pe investors active in healthcare & life sciences.